Cell-based therapy in ischemic stroke.
Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.
Hess
David C
DC
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA. dhess@mail.mcg.edu
Borlongan
Cesar V
CV
D002545:Brain Ischemia / Q000150:complications / Q000601:surgery*; D006801:Humans; D033581:Stem Cell Transplantation / Q000379:methods* / Q000639:trends*; D020521:Stroke / Q000150:complications / Q000601:surgery*; D016896:Treatment Outcome